Guggenheim Maintains Buy on Tenax Therapeutics, Raises Price Target to $25

Benzinga · 2d ago
Guggenheim analyst Seamus Fernandez maintains Tenax Therapeutics (NASDAQ:TENX) with a Buy and raises the price target from $14 to $25.